V.S. Sakalo, О.A. Chernichenko, Ю.M. Bondarenko, A.V. Sakalo, V.V. Mrachkovsky, P.G. Yakovlev, Y.Y. Kuranov, D.I. Kovalchuk
Disorder of bone mineral density in patients with locally advanced prostate cancer receiving hormone therapy
The purpose of the study was to evaluate the action of androgen-suppressive therapy (AST) on bone metabolism of patients with locally advanced prostate cancer (PC). Results. Osteoporotic vertebral deformities were found in 11 patients (45.8%) of the 1st group and 5 (10.9%) of the 2nd group. Spine fracture was diagnosed in 1 patient, who had previously undergone bilateral orchiectomy (BO) 5 years ago. In the control group vertebral deformity was found in 1 patient (5%) without fracture. According to the x-ray bone densitometry (DEXA) osteoporosis is detected in 13 patients with PC of the 1st group (54.2%), and 14 (30.4%) of the 2nd group. Osteopenia was observed in 9 (37.5%) patients of the 1st group and 28 (60.9%) of the 2nd group. In 1st group osteoporosis is detected in 4 (16.7%) patients with the duration of AST less than 3 years and 9 (37.5%) - over 3 years. In the 2nd group, osteoporosis is revealed in 5 (11.0%) patients with the duration of AST less than 3 years and 9 (19.6%) patients over 3 years. Testosterone was reduced in all patients. Mean parathyroid hormone under conservative therapy was 18,2 ± 1,8 ng/ml and - 21,1 ± 1,4 ng/ml in patients after BO. The level of alkaline phosphatase in the 1st group was 52 IU/L, 46 IU/L - in the 2nd group, 38 IU/l - in the control group.